ID	3.2.1.49
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   (#1# AdhA fragment <20,21,22>) <20,21,22,36>
PR	#2# Mus musculus   <26,27>
PR	#3# Homo sapiens   <1,2,8,9,12,13,15,19,23,30,32,33,37,39,41,44,45>
PR	#4# Sus scrofa   <11,16>
PR	#5# Bos taurus   <16,17>
PR	#6# Aspergillus niger   <25,40,42>
PR	#7# Streptococcus equinus   <6>
PR	#8# Bacteroides fragilis   <6>
PR	#9# Selenomonas ruminantium   <6>
PR	#10# Megasphaera elsdenii   <6>
PR	#11# Ruminococcus albus   <6>
PR	#12# Helix pomatia   <18>
PR	#13# Butyrivibrio fibrisolvens   <6>
PR	#14# Clostridium perfringens   <10,29,34,35,38>
PR	#15# Fibrobacter succinogenes   <6>
PR	#16# Todarodes pacificus   (#16# IMPDH1 <7>) <7>
PR	#17# Patella vulgata   <14>
PR	#18# Lachnospira multipara   <6>
PR	#19# Katsuwonus pelamis   <4>
PR	#20# Ruminococcus torques   <24>
PR	#21# Human immunodeficiency virus 1   <37>
PR	#22# Ruminococcus flavefaciens   <6>
PR	#23# Eudiplodinium maggii   <6>
PR	#24# Acremonium sp.   <3>
PR	#25# Solenocera melantho   (#25# gene MdF3HIIb <5>) <5>
PR	#26# Entodinium caudatum   <6>
PR	#27# Ruminobacter amylophilus   <6>
PR	#28# Succinivibrio dextrinosolvens   <6>
PR	#29# Eubacterium ruminantium   <6>
PR	#30# Epidinium ecaudatum caudatum   <6>
PR	#31# Eremoplastron bovis   <6>
PR	#32# Entodinium simplex   <6>
PR	#33# Arenibacter latericius   <28>
PR	#34# Clostridium perfringens Q8XNK8 UniProt <31>
PR	#35# Homo sapiens P17050 UniProt <46>
PR	#36# Asterina amurensis   <44>
PR	#37# Architeuthis sp.   <43>

RECOMMENDED_NAME
RN	alpha-N-acetylgalactosaminidase


SYSTEMATIC_NAME
SN	alpha-N-acetyl-D-galactosaminide N-acetylgalactosaminohydrolase


SYNONYMS
SY	 alpha-acetylgalactosaminidase
SY	 N-acetyl-alpha-D-galactosaminidase
SY	 N-acetyl-alpha-galactosaminidase
SY	 4-nitrophenyl-alpha-N-acetylgalactosaminidase
SY	 2-acetamido-2-deoxy-alpha-D-galactoside acetamidodeoxygalactohydrolase
SY	 exo-alpha-N-acetylgalactosaminidase
SY	#1,35# alpha-NAGAL <36,46>
SY	#14# alpha-N-acetylgalactosaminidase blood group A2 degrading enzyme
	<38>
SY	#3# alpha-galactosidase B <32>
SY	#3# alpha-GalNAc <32>
SY	#3# alpha-NaGalase <30,33>
SY	#3# alpha-NAGA <39>
SY	#3# NagA <41,45>
SY	#3# alpha-GalNAcase <44>
SY	#3,21# NaGalase <37>
SY	#3,21# envelope glycoprotein gp160 <37>
SY	#33# alpha-N-galactosaminidase IV <28>
SY	#36,37# alpha-GalNAcase I <43,44>
SY	#36,37# alpha-GalNAcase II <43,44>

CAS_REGISTRY_NUMBER
CR	9075-63-2

REACTION
RE	cleavage of nonreducing alpha-(1->3)-N-acetylgalactosamine residues
	from human blood group A and AB mucin glycoproteins, Forssman hapten
	and blood group A lacto series glycolipids
 (#1# double-displacement
	mechanism. First step: an oxygen atom from Asp140 attacks the
	electrophilic C1 of the hexose ring, cleaving the glycosidic linkage
	and creating a covalent enzyme-substrate intermediate. The second step
	involves a nucleophilic attack by a water molecule, which has been
	deprotonated by Asp201, on the covalent intermediate. <36>; #3# the
	enzyme exhibits an endo-enzyme activity in addition to an exo-activity
	<33>; #35# double-displacement, or ping-pong, reaction mechanism and
	active site structure, overview <46>)

REACTION_TYPE
RT	hydrolysis of O-glycosyl bond

SOURCE_TISSUE
ST	#1,3,4,16,17,19,36,37# liver <1,4,7,11,12,13,14,15,21,41,43,44>
ST	#12,25# hepatopancreas <5,18>
ST	#21# viral envelope <37>
ST	#3# embryo <33>
ST	#3# HEL cell (#3# 299, low levels <33>) <33>
ST	#3# placenta <41,44>
ST	#3# fibroblast (#3# low levels, embryonic lung and gingival <33>; #3#
	from a patient with Fabry disease <41>) <8,33,41>
ST	#3# kidney <41>
ST	#3# heart <41>
ST	#3# lung <33,37>
ST	#3# lymphocyte <9>
ST	#3# leukocyte <2,9>
ST	#3# Hep-G2 cell <30>
ST	#3# serum (#3# specific enzymatic activity of serum
	alpha-N-acetylgalactosaminidase is significantly increased in stage III
	melanoma patients, but not in early stages <45>) <37,45>
ST	#3# blood plasma <39,41>
ST	#3# melanoma cell (#3# cutaneous melanoma, specific enzymatic activity
	of serum alpha-N-acetylgalactosaminidase is significantly increased in
	stage III melanoma patients, but not in early stages <45>) <45>
ST	#3# plasma <39>
ST	#3# keratinocyte (#3# low levels <33>) <33>
ST	#3# mononuclear cell (#3# peripheral blood, inducible enzyme <37>) <37>
ST	#3# lymphoid tissue <9>
ST	#3# B-lymphocyte (#3# inducible enzyme <37>) <37>
ST	#3# B16-F10 cell <45>
ST	#3# HCT-116 cell <30>
ST	#3# carcinoma (#3# high levels, salivary gland and gingival <33>) <33>
ST	#3# Chang liver cell <30>
ST	#36# alimentary canal <44>
ST	#5# spleen <17>

LOCALIZATION
LO	#3# membrane <37>
LO	#3,4,35# lysosome <16,39,46>
LO	#3,6# extracellular (#3# serum enzyme <45>) <41,42,45>

NATURAL_SUBSTRATE_PRODUCT
NSP	#14# blood group A glycoconjugate + H2O = ? (#14#
	alpha-N-acetylgalactosaminidase blood group A2 degrading activity,
	substrate from human erythrocytes and plasma <38>) <38>
NSP	#21# serum vitamin D3-binding protein + H2O = ? (#21# i.e. Gc protein,
	the human substrate is the precursor of the principal macrophage
	activating factor, MAF, the deglycosylated prrecursor cannot be
	converted, which leads to immunosuppression <37>) <37>
NSP	#3,21,35,36# More = ? (#3# enzyme deficiency, due to missense mutations
	at residue R329 causing structural changes in the enzyme leading to
	differing substrate specificity, causes the Kanzaki disease, an
	autosomal recessine storage disorder with accumulation of
	GalNAcalpha1-O-Ser/Thr in the lysosome and increased urinary excretion
	of O-linked sialylglycopeptides, phenotype, overview <39>; #21# the
	enzyme plays a dual role in regulating both infectivity and
	immunosuppression <37>; #35# alpha-NAGAL is a lysosomal exoglycosidase
	that cleaves terminal alpha-N-acetylgalactosamine residues from
	glycopeptides and glycolipids <46>; #3,36# the enzyme hydrolyzes
	alpha-N-acetylgalactosyl residues from glycolipids and glycoproteins
	<44>) {} <37,39,44,46>

SUBSTRATE_PRODUCT
SP	#1,3# o-nitrophenyl-alpha-N-acetylgalactosaminide + H2O = o-nitrophenol
	+ alpha-N-acetylgalactosamine <13,20>
SP	#1,6,20# p-nitrophenyl-alpha-N-acetylgalactosaminide + H2O =
	p-nitrophenol + alpha-N-acetylgalactosamine <22,24,25>
SP	#14# o-nitrophenyl-N-acetyl-alpha-D-galactosaminide + H2O =
	o-nitrophenol + N-acetyl-alpha-D-galactosamine (#14# substrate from the
	blood type A2 antigen producing H antigen, blood type O <35>) <34,35>
SP	#14# blood group A glycoconjugate + H2O = ? (#14#
	alpha-N-acetylgalactosaminidase blood group A2 degrading activity,
	substrate from human erythrocytes and plasma <38>; #14#
	alpha-N-acetylgalactosaminidase blood group A2 degrading activity,
	substrate from human and murine erythrocytes and plasma <38>) <38>
SP	#14# 4-nitrophenyl-N-acetyl-alpha-D-galactosamide + H2O = 4-nitrophenol
	+ N-acetyl-alpha-D-galactosamine <38>
SP	#14,34# p-nitrophenyl-N-acetyl-alpha-D-galactosaminide + H2O =
	p-nitrophenol + N-acetyl-alpha-D-galactosamine <31,34,35>
SP	#19# ovine submaxillary asialoglycoprotein + H2O = ? <4>
SP	#3# p-nitrophenyl-2-deoxy-alpha-D-galactopyranoside + H2O =
	p-nitrophenol + 2-deoxy-alpha-D-galactopyranose <1>
SP	#3# 4-methylumbelliferyl-alpha-D-galactopyranoside + H2O =
	4-methylumbelliferone + alpha-D-galactopyranose (#3# substrate of
	engineered enzyme mutant S188E/A191L, not of the wild-type enzyme <41>)
	<12,41>
SP	#3# globotriaosylceramide + H2O = ? (#3# wild-type and engineered
	mutant enzymes <41>) <41>
SP	#3# p-nitrophenyl
	2-acetamide-2-deoxy-3-O-(beta-D-galactopyranosyl)-alpha-D
	galactopyranoside + H2O = p-nitrophenol +
	2-acetamide-2-deoxy-3-O-(beta-D-galactopyranosyl)-alpha-D
	galactopyranoside <33>
SP	#3# p-nitrophenyl alpha-D-galactopyranoside + H2O = p-nitrophenol +
	alpha-D-galactopyranose <33>
SP	#3# p-nitrophenyl N-acetyl-alpha-D-galactosaminide + H2O =
	p-nitrophenol + N-acetyl-alpha-D-galactosamine <33>
SP	#3# p-nitrophenyl-alpha-N-acetyl-D-galactoaminide + H2O = p-nitrophenol
	+ alpha-N-acetyl-D-galactosamine (#3# the Hep-G2 cell lysate hydrolyzes
	the exo-type substrate <30>) <30>
SP	#3# 4-methylumbelliferyl-alpha-D-galactosaminide + H2O =
	4-methylumbelliferone + alpha-D-galactosamine <39>
SP	#3# GalNAc-alpha1-O-Ser + H2O = ? <39>
SP	#3# GalNAc-alpha1-O-Thr + H2O = ? <39>
SP	#3# p-nitrophenyl N-acetyl-alpha-D-galactosaminide + H2O =
	p-nitrophenol + N-acetyl-D-galactosamine <37>
SP	#3,21# serum vitamin D3-binding protein + H2O = ? (#21# i.e. Gc
	protein, the human substrate is the precursor of the principal
	macrophage activating factor, MAF, the deglycosylated prrecursor cannot
	be converted, which leads to immunosuppression <37>; #3,21# i.e. Gc
	protein, human substrate, deglycosylation of the substrate <37>) <37>
SP	#3,35,37# 4-nitrophenyl alpha-D-N-acetylgalactosaminide + H2O =
	4-nitrophenol + N-acetyl-D-galactosamine (#35# substrate binding and
	active site structure, active-site interactions and ligand binding,
	overview. Inactive enzyme conformation, overview <46>) <43,45,46>
SP	#3,36#
	GalNAc-alpha-1,3-GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-beta-1
	1-ceramide + H2O = alpha-N-acetylgalactosamine +
	GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-beta-1,1-ceramide (#3#
	i.e. Forssman hapten glycolipid <44>; #36# i.e. Forssman hapten
	glycolipid, production of globoside by both isozymes <44>) <44>
SP	#3,4,20# Forssman hapten + H2O = ? <11,13,24>
SP	#3,6,14,21,35,36# More = ? (#3# Gal-beta-GalNAc-alpha-PNP is no
	substrate for Hep-G2 cell lysate, the enzyme of tumor cell lysate
	reduces the macrophage activing potency of GcMAF <30>; #14# the enzyme
	hydrolyzes the terminal N-actyl-alpha-D-galactosamine from the blood
	type A2 antigen producing H antigen, blood type O <29>; #3# the enzyme
	inactivates the macrophage activing factor produced from Gc protein and
	this results in reduced phagocytic activity and superoxide-generation
	capacity of monocytes/macrophages <33>; #3# the enzyme is highly
	selective for terminal N-acetylgalactosamine residues <32>; #14# the
	enzyme is highly selective for terminal N-acetylgalactosamine residues,
	sugars other than N-acetyl-alpha-D-galactosaminide are no substrates
	<35>; #14# the enzyme is highly selective for terminal
	N-acetylgalactosamine residues, sugars other than
	N-acetyl-alpha-D-galactosaminide are not substrates. the enzyme
	degrades blood A epitope <34>; #3# enzyme deficiency, due to missense
	mutations at residue R329 causing structural changes in the enzyme
	leading to differing substrate specificity, causes the Kanzaki disease,
	an autosomal recessine storage disorder with accumulation of
	GalNAcalpha1-O-Ser/Thr in the lysosome and increased urinary excretion
	of O-linked sialylglycopeptides, phenotype, overview <39>; #21# the
	enzyme plays a dual role in regulating both infectivity and
	immunosuppression <37>; #21# the HIV-1 viral envelope glycoprotein
	gp160 shows alpha-N-galactosaminidase activity <37>; #35# alpha-NAGAL
	is a lysosomal exoglycosidase that cleaves terminal
	alpha-N-acetylgalactosamine residues from glycopeptides and glycolipids
	<46>; #3,36# the enzyme hydrolyzes alpha-N-acetylgalactosyl residues
	from glycolipids and glycoproteins <44>; #3# Ser188 and Ala191 play
	important roles in the recognition of an N-acetylgalactosamine residue
	in NAGA <41>; #35# the enzyme also shows activity with 4-nitrophenyl
	alpha-D-galactosaminide <46>; #6# the enzyme glycosylizes free serine
	and threonine residues in the native and the
	N-tert-butoxycarbonyl-protected analogue protein to gain the Tn
	antigen. The enzyme catalyzes glycosylations yielding to a series of
	2-acetamido-2-deoxy-alpha-D-galactobiosides using
	2-acetamido-2-deoxy-D-galactopyranose as a glycosyl donor,
	identification of isomers alpha-D-GalpNAc-1,6-D-GalpNAc,
	alpha-D-GalpNAc-1,3-D-GalpNAc, and alpha-D-GalpNAc-1,6-D-GalfNAc <42>)
	{} <29,30,32,33,34,35,37,39,41,42,44,46>
SP	#33# p-nitrophenyl-alpha-N-acetyl-D-galactosaminide + H2O =
	p-nitrophenol + alpha-N-acetyl-D-galactosamine <28>
SP	#5# phenyl-alpha-N-acetylglucosaminide + H2O = N-acetylgalactosamine +
	phenol <17>
SP	#6# 2-nitrophenyl-alpha-N-acetylgalactosaminide + H2O = 2-nitrophenol +
	alpha-N-acetylgalactosamine (#6# enzyme acts with retention of the
	anomeric configuration <40>) {?} <40>

TURNOVER_NUMBER
TN	#35# 16.3 {4-nitrophenyl alpha-D-N-acetylgalactosaminide}  (#35#
	recombinant wild-type enzyme <46>) <46>
TN	#35# 17.1 {4-nitrophenyl alpha-D-N-acetylgalactosaminide}  (#35#
	recombinant mutant N201Q <46>) <46>

KM_VALUE
KM	#1# 2.4 {o-nitrophenyl-alpha-N-acetylgalactosaminide}  <20>
KM	#1,25# 0.8 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <5,22>
KM	#1,3,4,35# -999 {more}  (#35# kinetics, recombinant wild-type and
	mutant enzymes <46>) <11,12,19,20,33,46>
KM	#14# 0.77 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <10>
KM	#14# 1.1 {p-nitrophenyl-N-acetyl-alpha-D-galactosaminide}  (#14# pH
	6.5, 37°C, recombinant enzyme <35>) <35>
KM	#14# 1.35 {p-nitrophenyl-N-acetyl-alpha-D-galactosaminide}  (#14# pH
	7.0, 37°C <34>) <34>
KM	#14# 1.58 {o-nitrophenyl-N-acetyl-alpha-D-galactosaminide}  (#14# pH
	7.0, 37°C <34>) <34>
KM	#14# 1.62 {o-nitrophenyl-N-acetyl-alpha-D-galactosaminide}  (#14# pH
	6.5, 37°C, recombinant enzyme <35>) <35>
KM	#16# 3.33 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  (#16#
	isoenzyme I <7>) <7>
KM	#16# 1.55 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  (#16#
	isoenzyme II <7>) <7>
KM	#17# 0.6 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <14>
KM	#17# 0.036 {Forssman hapten}  <14>
KM	#19# 0.05 {ovine submaxillary asialoglycoprotein}  <4>
KM	#19# 4.2 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <4>
KM	#20# 2.2-5.8 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  (#20# three
	isoforms <24>) <24>
KM	#21# 4.83 {serum vitamin D3-binding protein}  (#21# pH 4.3, 37°C <37>)
	<37>
KM	#24# 1.3 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <3>
KM	#3# 1.3 {o-nitrophenyl-alpha-N-acetylgalactosaminide}  <13>
KM	#3# 7 {N-acetyl-alpha-D-galactosaminide}  <23>
KM	#3# 2.4 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <9>
KM	#3# 0.59 {Forssman hapten}  <13>
KM	#3# 6.8 {4-methylumbelliferyl-alpha-D-galactopyranoside}  <12,13>
KM	#3# 8.8 {o-nitrophenyl-alpha-D-fucopyranoside}  <1>
KM	#3# 1.27 {p-nitrophenyl N-acetyl-alpha-D-galactosaminide}  (#3# enzyme
	from HIV patient serum, at pH 6.1 <37>) <37>
KM	#3# 1.27 {serum vitamin D3-binding protein}  (#3# pH 6.1, 37°C <37>)
	<37>
KM	#3# 14.7 {p-nitrophenyl-2-deoxy-alpha-D-galactopyranoside}  <1>
KM	#3# 1.79
	{GalNAc-alpha-1,3-GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-beta-1
	1-ceramide}  (#3# pH 4.2, 37°C <44>) <44>
KM	#3# 4.83 {p-nitrophenyl N-acetyl-alpha-D-galactosaminide}  (#3#
	constitutive lung enzyme, at pH 4.3 <37>) <37>
KM	#33# 0.38 {p-nitrophenyl-alpha-N-acetyl-D-galactosaminide}  (#33# pH
	7.2, 36°C <28>) <28>
KM	#35# 0.089 {4-nitrophenyl alpha-D-N-acetylgalactosaminide}  (#35#
	recombinant mutant N201Q <46>) <46>
KM	#35# 0.07 {4-nitrophenyl alpha-D-N-acetylgalactosaminide}  (#35#
	recombinant wild-type enzyme <46>) <46>
KM	#36# 1.04
	{GalNAc-alpha-1,3-GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-beta-1
	1-ceramide}  (#36# pH 4.2, 37°C, isozyme alpha-GalNAcase I <44>) <44>
KM	#36# 3.97
	{GalNAc-alpha-1,3-GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-beta-1
	1-ceramide}  (#36# pH 4.2, 37°C, isozyme alpha-GalNAcase II <44>) <44>
KM	#4# 2.5 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <11>
KM	#4# 6.6 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <16>
KM	#5# 50 {phenyl-alpha-N-acetylglucosaminide}  <17>
KM	#6# 0.23 {p-nitrophenyl-alpha-N-acetylgalactosaminide}  <25>
KM	#6# 0.73 {2-nitrophenyl-alpha-N-acetylgalactosaminide}  (#6# pH 3.0,
	35°C <40>) <40>

PH_OPTIMUM
PHO	#1# 3.7 <20,22>
PHO	#14# 6.5 (#14# assay at <38>) <38>
PHO	#14# 6.5-7 (#14# recombinant enzyme <35>) <34,35>
PHO	#16# 2.7-3.5 (#16# isoenzyme I,
	p-nitrophenyl-alpha-N-acetylgalactosaminide <7>) <7>
PHO	#17,25# 3.8 (#17,25# p-nitrophenyl-alpha-N-acetylgalactosaminide
	<5,14>) <5,14>
PHO	#19# 4 (#19# p-nitrophenyl-alpha-N-acetylgalactosaminide <4>) <4>
PHO	#20# 5.8-6.8 (#20# three isoforms <24>) <24>
PHO	#24# 4-4.5 (#24# p-nitrophenyl-alpha-N-acetylgalactosaminide <3>) <3>
PHO	#3# 4.8 (#3# 4-methylumbelliferyl-alpha-galactopyranoside <12>) <12>
PHO	#3# 4.5 (#3# 4-methylumbelliferyl-alpha-galactopyranoside <2>; #3#
	N-acetyl-alpha-D-galactosaminide <23>) <2,23>
PHO	#3# 6.1 (#3# enzyme from HIV patient serum <37>) <37>
PHO	#3# 4-6.8 <33>
PHO	#3,14# 6 (#3# assay at <45>; #14#
	p-nitrophenyl-alpha-N-acetylgalactosaminide <10>) <10,45>
PHO	#3,16# 4.2 (#16# isoenzyme II,
	p-nitrophenyl-alpha-N-acetylgalactosaminide <7>) <7,44>
PHO	#3,21# 4.3 (#3# constitutive lung enzyme <37>) <37>
PHO	#3,4# -999 (#3# other substrates <12>; #4# more values of isoenzymes
	<16>) <12,16>
PHO	#33# 7-8 (#33# pH 7.2, 36°C <28>) <28>
PHO	#36# 3 (#36# isozyme alpha-GalNAcase II <44>) <44>
PHO	#36# 3.5 (#36# isozyme alpha-GalNAcase I <44>) <44>
PHO	#4# 3.9 (#4# forssman hapten <11>) <11>
PHO	#4,5# 4.3-4.7 (#4,5# p-nitrophenyl-alpha-N-acetylgalactosaminide
	<11,16>) <11,16>
PHO	#6# 1.8 <40>
PHO	#6# 2.6-3.2 <25>

PH_RANGE
PHR	#14# 6-8 (#14# 27% decline in activity from pH 6.0-8.0 with no apparent
	optimum <29>) <29>
PHR	#14# 6.4-7 <38>
PHR	#19# 4-7 (#19# not active above,
	p-nitrophenyl-alpha-N-acetylgalactosaminide <4>) <4>
PHR	#20# 5-9.5 <24>
PHR	#24# 2.5-8 (#24# p-nitrophenyl-alpha-N-acetylgalactosaminide <3>) <3>
PHR	#3# 3-8 (#3# below pH 3.6 the activity declines rapidly and at pH 3.0
	retains about 1% of the orginal activity, above pH 7.5 the activity
	declines rapidly and at pH 8.0 retains about 4% of the orginal activity
	<33>) <33>

SPECIFIC_ACTIVITY
SA	#1# 51.2 (#1# recombinant enzyme <22>) <22>
SA	#1# 56.4 (#1# native enzyme <22>) <22>
SA	#14# 84.11 <35>
SA	#14# 43.92 <34>
SA	#14# 84110.0 (#14# purified recombinant enzyme <38>) <38>
SA	#3# 4.5 (#3# purified placental enzyme <44>) <44>
SA	#3# 0.012 (#3# cell extract of salivary gland carcinoma <33>) <33>
SA	#3# 0.0004 (#3# cell extract of embryonic lung fibroblast <33>) <33>
SA	#3# 0.0021 (#3# pH 5.0, Hep-G2 cell <30>) <30>
SA	#3# 0.005 (#3# cell extract of gingival carcinoma <33>) <33>
SA	#3# 0.0026 (#3# pH 5.0, HCT116 cell <30>) <30>
SA	#3# 8.33 (#3# purified recombinant enzyme mutant <41>) <41>
SA	#3# 0.0002 (#3# cell extract of gingival keratinocyte <33>) <33>
SA	#3# 0.0012 (#3# pH 5.0, Chang liver cell <30>) <30>
SA	#3# 0.0003 (#3# cell extract of gingival fibroblast <33>) <33>
SA	#3# 2279.0 (#3# purified fraction from salivary gland carcinoma <33>)
	<33>
SA	#3,7,8,9,10,11,13,15,18,21,22,23,26,27,28,29,30,31,32,33# -999.0 (#26#
	list of rumen bacteria and protozoa <6>) <6,28,32,37,39>
SA	#36# 24.2 (#36# purified isozyme alpha-GalNAcase II <44>) <44>
SA	#36# 19.56 (#36# purified isozyme alpha-GalNAcase I <44>) <44>
SA	#6# 33.5 (#6# pH 3.0, 35°C <40>) <40>

TEMPERATURE_OPTIMUM
TO	#3,14,21,36# 37 (#3,21,36# assay at <37,44,45>) <10,23,37,38,44,45>
TO	#6# 55 <40>

ACTIVATING_COMPOUND
AC	#21# Trypsin (#21# the enzyme needs to be proteolytically activated,
	activation of the enzyme by trypsin <37>) <37>
AC	#3# more (#3# the enzyme is inducible in patients peripheral blood
	mononuclear cells by HIV-1 provirus-inducing agent, overview <37>) <37>

INHIBITORS
IN	#3# D-glucose <44>
IN	#3# K+ <44>
IN	#3# Mg2+ <44>
IN	#3# Mn2+ <44>
IN	#3# N-acetyl-D-glucosamine <44>
IN	#3# Na+ <44>
IN	#3# SDS <2>
IN	#3# Zn2+ <44>
IN	#3,16,17,25,36# Ag+ (#16# isoenzyme II <7>; #36# moderate inhibition of
	isozyme alpha-GalNAcase I, strong inhibition of isozyme alpha-GalNAcase
	II <44>) <2,5,7,14,44>
IN	#3,16,17,25,36# D-galactose (#16# isoenzyme I <7>; #36# about 10%
	inhibition of isozymes alpha-GalNAcase I and isozyme alpha-GalNAcase II
	<44>) <5,7,14,23,44>
IN	#3,16,20# Cu2+ (#16# isoenzyme II <7>) <2,7,24,44>
IN	#3,33# Ca2+ (#33# 1 mM, complete loss of activity <28>) <28,44>
IN	#3,36# N-Acetyl-D-galactosamine (#36# 57% and 62% inhibition of isozyme
	alpha-GalNAcase I and isozyme alpha-GalNAcase II <44>) <44>
IN	#3,6,14,16,17,20,24,36# Hg2+ (#16# isoenzyme II <7>; #6# 10 mM, 12%
	residual activity <40>; #36# slight inhibition of isozyme
	alpha-GalNAcase I, strong inhibition of isozyme alpha-GalNAcase II
	<44>) <3,7,10,14,24,40,44>
IN	#33# Acetylimidazole (#33# 5 mM, 30% of original activity <28>) <28>
IN	#33# carbodiimide (#33# 1.8 mM, complete loss of activity <28>) <28>
IN	#33# Diethylpyrocarbonate (#33# 2 mM, 60% of original activity <28>)
	<28>
IN	#33# N-Bromosuccinimide (#33# 1.8 mM, complete loss of activity <28>)
	<28>
IN	#33# N-ethylmaleimide (#33# 1.8 mM, 60% of original activity <28>) <28>
IN	#33# p-chloromercuribenzoate (#33# 1.8 mM, complete loss of activity
	<28>) <28>
IN	#33# 2,2'-dianisidine (#33# 2 mM, 70% of original activity <28>) <28>
IN	#4# Fe2+ <16>
IN	#4,16,17,25# N-acetylgalactosamine <5,7,14,16>
IN	#6# Pb2+ (#6# 10 mM, 30% residual activity <40>) <40>
IN	#6,36# more (#6# not inhibitory: Ca2+, Mg2+, Mn2+, Ag+ <40>; #36# no
	inhibition by D-glucose, N-acetyl-D-glucosamine, and Mn2+ <44>) <40,44>

METALS_IONS
ME	#33,36# Mg2+ (#33# activates <28>; #36# slight activation of both
	isozymes <44>) <28,44>
ME	#36# Ca2+ (#36# slight activation of both isozymes <44>) <44>
ME	#36# Cu2+ (#36# slight activation of both isozymes <44>) <44>
ME	#36# K+ (#36# slight activation of both isozymes <44>) <44>
ME	#36# Na+ (#36# slight activation of both isozymes <44>) <44>
ME	#36# Zn2+ (#36# slight activation of both isozymes <44>) <44>

MOLECULAR_WEIGHT
MW	#19# 80000 (#19# pH 4.2, gel filtration <4>) <4>
MW	#19,36# 40000 (#19# pH 7.2, gel filtration <4>; #36# isozyme
	alpha-GalNAcase II, gel filtration <44>) <4,44>
MW	#24,25# 55000 (#24# gel filtration <3>) <3,5>
MW	#3# 48000 (#3# gel filtration <8>) <8>
MW	#33# 84000 (#33# gel filtration <28>) <28>
MW	#36# 430000 (#36# about, isozyme alpha-GalNAcase I, gel filtration
	<44>) <44>
MW	#4# 102000 (#4# gel filtration <11>) <11>
MW	#6# 115000 (#6# non-denaturating polyacrylamide gel electrophoresis
	<25>) <25>
MW	#6# 440000 (#6# gel filtration <40>) <40>

POSTTRANSLATIONAL_MODIFICATION
PM	#3,4,6,35# glycoprotein (#3# precursor is processed to the mature
	protein <8>; #4# 7.0% neutral sugars <11>; #6# enzyme may be
	deglycosylated without loss of activity <40>; #35# the enzyme contains
	five N-linked glycosylation sites. The N201 glycosylation is critical
	for enzyme stability and activity <46>) <8,11,40,46>

SUBUNITS
SU	#1,20# multimer (#1# x * 49100, SDS-PAGE <20>; #20# 160000-200000,
	SDS-PAGE, three isoforms <24>) <20,24>
SU	#1,24,36# monomer (#24# 57000, SDS-PAGE <3>; #1# 43000, SDS-PAGE <22>;
	#36# 1 * 43000, isozyme alpha-GalNAcase II, SDS-PAGE <44>) <3,22,44>
SU	#17# tetramer (#17# 4 * 50000, SDS-PAGE <14>) <14>
SU	#3,14,34# ? (#3# x * 48000, SDS-PAGE <33>; #34# x * 70000, SDS-PAGE
	<31>; #14# x * 719600, denatured recombinant enzyme, x * 724200, native
	recombinant enzyme, SDS-PAGE <35>; #14# x * 72100 Da, SDS-PAGE <34>;
	#3# x * 46000, native enzyme, SDS-PAGE <44>) <31,33,34,35,44>
SU	#3,37# More (#3# study of oligosaccharide structure, the first five:
	N124, N177, N201, N359 and N385, of six potential N-glycosylation sites
	are occupied <32>; #37# isozyme alpha-GalNAcase I and alpha-GalNAcase
	II peptide mapping and amino acid sequence comparisons, overview <43>)
	<32,43>
SU	#35# homodimer (#35# alpha-NAGAL is a homodimer with each monomer
	divided into two domains. Domain 1 forms a (beta/alpha)8 barrel, and
	domain 2 contains eight antiparallel beta strands in two beta sheets
	<46>) <46>
SU	#36# polymer (#36# x * 47000, isozyme alpha-GalNAcase I, SDS-PAGE <44>)
	<44>
SU	#4,19# dimer (#19# 2 * 35000, monomers associate to dimers at pH 4.2,
	SDS-PAGE <4>; #4# 2 * 52000, probably two subunits with identical
	molecular weight, SDS-PAGE <11>) <4,11>
SU	#6# hexamer (#6# 6 * 76000, SDS-PAGE <40>) <40>

PI_VALUE
PI	#3,6# 4.8 (#6# isoelectric focusing <40>; #3# purified enzyme,
	isoelectric focusing <44>) <40,44>
PI	#35# 4.58 (#35# recombinant enzyme <46>) <46>
PI	#36# 4.4 (#36# purified isozyme alpha-GalNAcase I, isoelectric focusing
	<44>) <44>
PI	#36# 7.1 (#36# purified isozyme alpha-GalNAcase II <44>) <44>

APPLICATION
AP	#3# biotechnology (#3# use of a modified
	alpha-N-acetylgalactosaminidase in the development of enzyme
	replacement therapy for Fabry disease <41>) <41>
AP	#3,14,33# medicine (#14# potential application in the field of
	erythrocyte conversion technology <34>; #3# the enzyme can be employed
	as a diagnostic/prognostic tool for patients with salivary gland
	adenocarcima <33>; #33# The enzyme is able to remove at neutral pH
	alpha-1,3-bound residues of N-acetylgalactosamine from glycoproteins of
	blood group A-substances and A-erythrocytes, converting them into 0
	group substances <28>; #14# the enzyme may be useful for enzymic
	conversion of type A2 to universally transfusable type O red blood
	cells, potential application in the field of solid organ
	transplantation <29>; #3# use of a modified
	alpha-N-acetylgalactosaminidase in the development of enzyme
	replacement therapy for Fabry disease <41>) <28,29,33,34,41>

ENGINEERING
EN	#3# N124Q (#3# 35% activity in comparison to 100% activity of wild-type
	enzyme <32>) <32>
EN	#3# N177Q (#3# 48% activity in comparison to 100% activity of wild-type
	enzyme <32>) <32>
EN	#3# N359Q (#3# 57% activity in comparison to 100% activity of wild-type
	enzyme <32>) <32>
EN	#3# N385Q (#3# 4% activity in comparison to 100% activity of wild-type
	enzyme <32>) <32>
EN	#3# S188E/A191L (#3# Ser188 and Ala191 play important roles in the
	recognition of an N-acetylgalactosamine residue in NAGA, while lu203
	and Leu206 play important roles in the recognition of a galactose
	residue in GLA. Construction of a modified
	alpha-N-acetylgalactosaminidase with alpha-galactosidase A-like
	substrate specificity. The enzyme acquires the ability to catalyze the
	degradation of 4-methylumbelliferyl-alpha-D-galactopyranoside, but
	retaines the wild-type NAGAs stability, overview <41>) <41>
EN	#3,35# N201Q (#3# 28% activity in comparison to 100% activity of
	wild-type enzyme <32>; #35# site-directed mutagenesis, one of the
	proteins with the third N-linked carbohydrate attachment site is
	removed <46>) <32,46>
EN	#3,35# R329W (#3# site-specific mutagenesis, construction of the
	naturally occurring mutation at R329 in Kanzaki disease, more severe
	phenotype compared to R329Q <39>; #3# mutation results in protein
	instability <39>; #35# a naturally occuring Schindler disease and/or
	Kanzaki disease mutation <46>) <39,46>
EN	#3,35# R329Q (#3# site-specific mutagenesis, construction of the
	naturally occurring mutation at R329 in Kanzaki disease, less severe
	phenotype compared to R329W <39>; #3# mutation results in protein
	instability <39>; #35# a naturally occuring Schindler disease and/or
	Kanzaki disease mutation <46>) <39,46>
EN	#35# more (#35# construction of mutants of each of the five N-linked
	glycosylation sites <46>) <46>
EN	#35# D217N (#35# a naturally occuring Schindler disease and/or Kanzaki
	disease mutation <46>) <46>
EN	#35# S160C (#35# a naturally occuring Schindler disease and/or Kanzaki
	disease mutation <46>) <46>
EN	#35# E193X (#35# a naturally occuring Schindler disease and/or Kanzaki
	disease mutation <46>) <46>
EN	#35# E325K (#35# a naturally occuring Schindler disease and/or Kanzaki
	disease mutation <46>) <46>
EN	#35# E367K (#35# a naturally occuring Schindler disease and/or Kanzaki
	disease mutation <46>) <46>

CLONED
CL	#1# (expression in yeast Pichia pastoris) <22>
CL	#1# (expression in bacteria, rabbit reticulocyte lysate and yeast) <21>
CL	#2# (expression in Cos-1 cells) <27>
CL	#2# (expression in B-lymphoblast cell line) <26>
CL	#3# (expression in Chines hamster ovary cells) <32>
CL	#3# (expression of the engineered enzyme in CHO cells) <41>
CL	#14# (expression of aagA gene in Escherichia coli, resulting in
	recombinants exhibiting high-level expression of the expected activity)
	<31>
CL	#14# (the gene encoding the clostridial enzyme is cloned in an
	Escherichia coli T7 expression system) <35>
CL	#35# (expression in CHO and COS-1 cells. Expression of wild-type and
	mutant enzymes in Escherichia coli as insoluble proteins, and in
	Kluyveromyces lactis as soluble hyperglycosylated proteins. Expression
	of wild-type and mutant enzymes in Trichoplusia ni Tn5 insect cells
	using the baculovirus transfection system leads to suitable proteins)
	<46>

CRYSTALLIZATION
CR	#1# (X-ray crystallography) <36>
CR	#35# (purified recombinant wild-type and mutant enzymes in complexes
	with two catalytic products, the alpha-galactose and alpha-GalNAc
	monosaccharides, and a covalent intermediate bound in the enzyme active
	site, X-ray diffraction structure determination and analysis at 1.9 A
	resolution) <46>

PURIFICATION
PU	#3# <8,12,13>
PU	#3# (enzyme from salivary gland cells) <33>
PU	#3# (enzyme mutant from cell culture by dialysis, ammonium sulfate
	fractionation, hydrophobic interaction, cation exchange, and anion
	exchange chromatography) <41>
PU	#3# (native enzyme from placenta by 4-aminophenyl
	thio-beta-D-galactose-ceramide hexoside-resin affinity) <44>
PU	#4# <11>
PU	#4# (partially) <16>
PU	#5# <17>
PU	#5# (partially) <16>
PU	#6# <40>
PU	#6# (native enzyme) <42>
PU	#12# <18>
PU	#14# <10,34>
PU	#14# (recombinant enzyme) <35>
PU	#16# <7>
PU	#17# <14>
PU	#19# <4>
PU	#24# <3>
PU	#25# <5>
PU	#33# <28>
PU	#36# (native isozymes alpha-GalNAcase I and II are isolated from liver
	homogenate by ammonium sulfate fractionation and separated from each
	other by gel filtration. Then they are further individually purified by
	cation exchange chromatography and gel filtration, and additionally by
	hydroxylapatite chromatography for isozyme alpha-GalNAcase II. Isozyme
	alpha-GalNAcase I is purified 440fold, isozyme alpha-GalNAcase II
	544fold) <44>
PU	#37# (native isozymes alpha-GalNAcase I and alpha-GalNAcase II from
	liver) <43>

PH_STABILITY
PHS	#14# 5-8 <35>
PHS	#16# 4.5-5.5 (#16# isoenzyme I <7>) <7>
PHS	#16# 4.5-6.5 (#16# isoenzyme II <7>) <7>
PHS	#17# 3.6-6.8 <14>
PHS	#19# 4-6 <4>
PHS	#20# 4.5-9.5 <24>
PHS	#24# 6-7.5 <3>
PHS	#25# 3-7.5 <5>
PHS	#3# -999 (#3# comparison of activity at pH 5.0, 6.0 and 7.0 from Hep-G2
	cells, HCT116 cells and Chang liver cells <30>) <30>
PHS	#3# 3.5-8.5 (#3# purified enzyme, stable at 4°C <44>) <44>
PHS	#36# 2.7-4.5 (#36# purified isozyme alpha-GalNAcase I, stable at 4°C
	<44>) <44>
PHS	#36# 2.3-6.5 (#36# purified isozyme alpha-GalNAcase II, stable at 4°C
	<44>) <44>
PHS	#6# 2.5-8 <25>
PHS	#6# 1.5-4 <40>

STORAGE_STABILITY
SS	#14# (4°C, 12 months) <34>
SS	#19# (0°C, sodium citrate buffer, bovine serum albumin, 2 weeks,  pH
	4.2) <4>
SS	#20# (4°C, enzyme separation buffer containing 3 mM sodium azide,
	25-31 months) <24>
SS	#24# (0°C, 1 month) <3>
SS	#3# (-20°C, acidified plasma, at least one year) <23>
SS	#3,14,19# (-20°C, lyophilized, several years) <4,8,10>
SS	#33# (20°C, stable for 1 week) <28>
SS	#33# (4°C, sterile condition, stable for any length of time) <28>
SS	#35# (the purified wild-type and N201Q mutant proteins expressed in
	insect cells retain nearly full activity for months at 4°C, but the
	CHO-expressed material loses most of its activity within 72 h) <46>
SS	#4,12# (-20°C, 6 months) <11,18>
SS	#6# (4°C, pH 1.5-4.0, stable for several months) <40>
SS	#6# (-20°C, about 5% loss of activity) <40>

TEMPERATURE_STABILITY
TS	#14# 4-45 <35>
TS	#14# 4-37 (#14# the enzyme hydrolyses A2 epitopes at 4°C with 42% of
	the efficiency of that at 37°C <29>) <29>
TS	#14# 4-24 (#14# active and stable at <38>) <38>
TS	#3# 42 (#3# comparison of stability at 42°C of mutant and wild-type
	enzymes <32>) <32>
TS	#3# 45 (#3# 55% loss of activity after 10 min <33>) <33>
TS	#3,17,19,24,25# 40 (#24# not stable above <3>; #3# 40% loss of activity
	after 30 min <33>) <3,4,5,14,33>
TS	#3,36# 37 (#3# stable for 6 h in 0.05 sodium citrate buffer, pH 4.2
	<33>; #36# pH 4.0,m 60 min, purified isozyme alpha-GalNAcase I shows
	50% remaining activity, purified isozyme alpha-GalNAcase II 92% <44>;
	#3# purified enzyme, 60 min, pH 4.0, 98% activity remaining <44>)
	<33,44>
TS	#33# -999 (#33# the enzyme does not withstand freezing <28>) <28>
TS	#6# 35 (#6# stable for at least 3 days <40>) <40>
TS	#6,16,33# 50 (#6# not stable above <25>; #16# isoenzyme I stable for 30
	min, isoenzyme II loses activity <7>; #33# at heating during 30 min
	retains 100% of the activity <28>) <7,25,28>
TS	#6,20# 55 (#20# not stable above <24>; #6# 5 h, 50% loss of activity
	<40>) <24,40>

REFERENCE
RF	<1> Dean, K.J.; Sweeley, C.C.: Studies on human liver
	alpha-galactosidases. III. Partial characterization of
	carbohydrate-binding specificities. J. Biol. Chem. (1979) 254,
	10006-10010. {Pubmed:226533}
RF	<2> Salvayre, R.; Maret, A.; Negre, A.; Douste-Blazy, L.: Properties of
	multiple molecular forms of alpha-galactosidase and
	alpha-N-acetylgalactosaminidase from normal and fabry leukocytes. Eur.
	J. Biochem. (1979) 100, 377-383. {Pubmed:41709}
RF	<3> Kadowaki, S.; Ueda, T.; Yamamoto, K.; Kumagai, H.; Tochikura, T.:
	Isolation and characterization of a blood group A substance-degrading
	alpha-N-acetylgalactosaminidase from an Acremonium sp.. Agric. Biol.
	Chem. (1989) 53, 111-120. {Pubmed:}
RF	<4> Nakagawa, H.; Asakawa, M.; Enomoto, N.: Purification and
	characterization of alpha-N-acetylgalactosaminidase from skipjack
	liver. J. Biochem. (1987) 101, 855-862. {Pubmed:3611044}
RF	<5> Chien, S.F.: Purification and characterization of
	alpha-N-acetylgalactosaminidase from shrimp hepatopancreas. J. Chin.
	Biochem. Soc. (1986) 15, 86-96. {Pubmed:}
RF	<6> Williams, A.G.; Withers, S.E.; Coleman, G.S.: Glycoside hydrolase
	of rumen bacteria and protozoa. Curr. Microbiol. (1984) 10, 287-294.
	{Pubmed:}
RF	<7> Itoh, T.; Uda, Y.: alpha-N-Acetylgalactosaminidase from squid
	liver: purification and characterization of two enzymes. J. Biochem.
	(1984) 95, 959-970. {Pubmed:6746602}
RF	<8> Sweeley, C.C.; Ledonne, N.C.; Robbins, P.W.: Post-translational
	processing reactions involved in the biosynthesis of lysosomal
	alpha-N-acetylgalactosaminidase in cultured human fibroblasts. Arch.
	Biochem. Biophys. (1983) 223, 158-165. {Pubmed:6859854}
RF	<9> Salvayre, R.; Negre, A.; Maret, A.; Lenoir, G.; Douste-Blazy, L.:
	Separation and properties of molecular forms of alpha-galactosidase and
	alpha-N-acetylgalactosaminidase from blood lymphocytes and lymphoid
	cell lines transformed by Epstein-Barr virus. Biochim. Biophys. Acta
	(1981) 659, 445-456. {Pubmed:6266491}
RF	<10> Levy, G.N.; Aminoff, D.: Purification and properties of
	alpha-N-acetylgalactosaminidase from Clostridium perfringens. J. Biol.
	Chem. (1980) 255, 11737-11742. {Pubmed:6254979}
RF	<11> Sung, S.S.J.; Sweely, C.C.: Purification and partial
	characterization of porcine liver alpha-N-acetylgalactosaminidase. J.
	Biol. Chem. (1980) 255, 6589-6594. {Pubmed:7391035}
RF	<12> Dean, K.J.; Sweeley, C.C.: Studies on human liver
	alpha-galactosidases. II. Purification and enzymatic properties of
	alpha-galactosidase B (alpha-N-acetylgalactosaminidase). J. Biol. Chem.
	(1979) 254, 10001-10005. {Pubmed:226532}
RF	<13> Dean, K.J.; Sung, S.S.J.; Sweeley, C.C.: The identification of
	alpha-galactosidase B from human liver as an
	alpha-N-acetylgalactosaminidase. Biochem. Biophys. Res. Commun. (1977)
	77, 1411-1417. {Pubmed:901541}
RF	<14> Uda, Y.; Li, S.C.; Li, Y.T.: alpha-N-Acetylgalactosaminidase from
	the limpet, Patella vulgata. J. Biol. Chem. (1977) 252, 5194-5200.
	{Pubmed:18458}
RF	<15> Callahan, J.W.; Lassila, E.L.; den Tandt, W.; Philippart, M.:
	alpha-N-Acetylgalactosaminidase: isolation, properties and distribution
	of the human enzyme. Biochem. Med. (1973) 7, 424-431. {Pubmed:4715567}
RF	<16> Weissmann, B.; Hinrichsen, D.F.: Mammalian
	alpha-acetylgalactosaminidase. Occurrence, partial purification, and
	action on linkages in submaxillary mucins. Biochemistry (1969) 8,
	2034-2043. {Pubmed:5785223}
RF	<17> Werries, E.; Wollek, E.; Gottschalk, A.; Buddecke, E.: Separation
	of N-acetyl-alpha-glucosaminidase and N-acetyl-alpha-galactosaminidase
	from ox spleen. Cleavage of the O-glycosidic linkage between
	carbohydrate and polypeptide in ovine and bovine submaxillary
	glycoprotein by N-acetyl-alpha-galactosaminidase. Eur. J. Biochem.
	(1969) 10, 445-449. {Pubmed:5348072}
RF	<18> Tuppy, H.; Staudenbauer, W.L.: The action on soluble blood group A
	substances of an alpha-N-acetylgalactosaminidase from Helix pomatia.
	Biochemistry (1966) 5, 1742-1747. {Pubmed:6006833}
RF	<19> Yagi, F.; Eckhardt, A.E.; Goldstein, I.J.: Gycosidases of Ehrlich
	ascites tumor cells and ascitic fluid-purification and substrate
	specificity of alpha-N-acetylgalactosaminidase and alpha-galactosidase:
	comparison with coffee bean alpha galactosidase. Arch. Biochem.
	Biophys. (1990) 280, 61-67. {Pubmed:2162155}
RF	<20> Hata, J.; Dhar, M.; Mitra, M.; Harmata, M.; Haibach, P.; Sun, P.;
	Smith, D.: Purification and characterization of
	N-acetyl-alpha-D-galactosaminidase from Gallus domesticus. Biochem.
	Int. (1992) 28, 77-86. {Pubmed:1445396}
RF	<21> Zhu, A.; Goldstein, J.: Cloning and characterization of a cDNA
	encoding chicken liver alpha-N-acetylgalactosaminidase. Gene (1993)
	137, 309-314. {Pubmed:8299964}
RF	<22> Zhu, A.; Monahan c.; Wang Z.; Goldstein J.: Expression,
	purification and characterization of recombinant
	alpha-N-acetylgalactosaminidase produced in the yeast Pichia pastoris.
	Protein Expr. Purif. (1996) 8, 456-462. {Pubmed:8954893}
RF	<23> Den Tandt, W.R.; Scharpe, S.: Micromethod for the fluorimetric
	determination of plasma N-acetyl-alpha-galactosaminidase and study of
	some of its characteristics. Enzyme Protein (1996) 49, 273-280.
	{Pubmed:9252785}
RF	<24> Hoskins, L.C.; Boulding, E.T.; Larson G.: Purification and
	characterization of blood group A-degrading isoforms of
	alpha-N-acetylgalactosaminidase from Ruminococcus torques strain IX-70.
	J. Biol. Chem. (1997) 272, 7932-7939. {Pubmed:9065462}
RF	<25> Naundorf, A.; Ajisaka, K.: Purification of
	alpha-N-acetylgalactosaminidase from Aspergillus niger and its use in
	the synthesis of GalNAc-alpha-(1 O)-serine. Enzyme Microb. Technol.
	(1999) 25, 483-488. {Pubmed:}
RF	<26> Hermann, T.; Schindler, D.; Tabe, H.; Onadera, O.; Igarashi, S.;
	Polack, A.; Zehnpfennig, D.; Tsuji S.: Molecular cloning, structural
	organization, sequence, chromosomal assignment, and expression of the
	mouse alpha-N-acetylgalactosaminidase gene. Gene (1998) 211, 205-214.
	{Pubmed:9602128}
RF	<27> Wang, A.M.; Ioannou, Y.A.; Zeidner, K.M.; Desnick, R.J.: Murine
	alpha-N-acetylgalactosaminidase: Isolation and expression of a
	full-lenght cDNA and genomic organization: further evidence of an alpha
	galactosidase gene family. Mol. Genet. Metab. (1998) 65, 165-173.
	{Pubmed:9787108}
RF	<28> Bakunina, I.Y.; Kuhlmann, R.A.; Likhosherstov, L.M.; Martynova,
	M.D.; Nedashkovskaya, O.I.; Mikhailov, V.V.; Elyakova, L.A.:
	Alpha-N-acetylgalactosaminidase from marine bacterium Arenibacter
	latericius KMM 426T removing blood type specificity of A-erythrocytes.
	Biochemistry (2002) 67, 689-695. {Pubmed:12126478}
RF	<29> Hsieh, H.Y.; Smith, D.: Clostridium perfringens
	alpha-N-acetylgalactosaminidase blood group A2-degrading activity.
	Biotechnol. Appl. Biochem. (2003) 37, 157-163. {Pubmed:12630904}
RF	<30> Mohamad, S.B.; Nagasawa, H.; Uto, Y.; Hori, H.: Tumor cell
	alpha-N-acetylgalactosaminidase activity and its involvement in
	GcMAF-related macrophage activation. Comp. Biochem. Physiol. A (2002)
	132, 1-8. {Pubmed:12062184}
RF	<31> Calcutt, M.J.; Hsieh, H.Y.; Chapman, L.F.; Smith, D.S.:
	Identification, molecular cloning and expression of an
	alpha-N-acetylgalactosaminidase gene from Clostridium perfringens. FEMS
	Microbiol. Lett. (2002) 214, 77-80. {Pubmed:12204375}
RF	<32> Ohta, M.; Ohnishi, T.; Ioannou, Y.A.; Hodgson, M.E.; Matsuura, F.;
	Desnick, R.J.: Human alpha-N-acetylgalactosaminidase: site occupancy
	and structure of N-linked oligosaccharides. Glycobiology (2000) 10,
	251-261. {Pubmed:10704524}
RF	<33> Matsuura, T.; Uematsu, T.; Yamaoka, M.; Furusawa, K.: Effect of
	salivary gland adenocarcinoma cell-derived
	alpha-N-acetylgalactosaminidase on the bioactivity of macrophage
	activating factor. Int. J. Oncol. (2004) 24, 521-528. {Pubmed:14767536}
RF	<34> Hsieh, H.Y.; Mitra, M.; Wells, D.C.; Smith, D.: Purification and
	characterization of alpha-N-acetylgalactosaminidase from Clostridium
	perfringens. IUBMB Life (2000) 50, 91-97. {Pubmed:11185964}
RF	<35> Hsieh, H.Y.; Calcutt, M.J.; Chapman, L.F.; Mitra, M.; Smith, D.S.:
	Purification and characterization of a recombinant
	alpha-N-acetylgalactosaminidase from Clostridium perfringens. Protein
	Expr. Purif. (2003) 32, 309-316. {Pubmed:14965778}
RF	<36> Garman, S.C.; Hannick, L.; Zhu, A.; Garboczi, D.N.: The 1.9 A
	structure of alpha-N-acetylgalactosaminidase: molecular basis of
	glycosidase deficiency diseases. Structure (2002) 10, 425-434.
	{Pubmed:12005440}
RF	<37> Yamamoto, N.: Pathogenic significance of
	alpha-N-acetylgalactosaminidase activity found in the envelope
	glycoprotein gp160 of human immunodeficiency virus Type 1. AIDS Res.
	Hum. Retroviruses (2006) 22, 262-271. {Pubmed:16545013}
RF	<38> Hsieh, H.; Chapman, L.F.; Calcutt, M.J.; Mitra, M.; Smith, D.S.:
	Recombinant Clostridium perfringens alpha-N-acetylgalactosaminidase
	blood group A2 degrading activity. Artif. Cells Blood Substit. Immobil.
	Biotechnol. (2005) 33, 187-199. {Pubmed:15960079}
RF	<39> Kanekura, T.; Sakuraba, H.; Matsuzawa, F.; Aikawa, S.; Doi, H.;
	Hirabayashi, Y.; Yoshii, N.; Fukushige, T.; Kanzaki, T.: Three
	dimensional structural studies of alpha-N-acetylgalactosaminidase
	(alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): different gene
	mutations cause peculiar structural changes in alpha-NAGAs resulting in
	different substrate specificities and clinical phenotypes. J. Dermatol.
	Sci. (2005) 37, 15-20. {Pubmed:15619430}
RF	<40> Weignerova, L.; Filipi, T.; Manglova, D.; Kren, V.: Induction,
	purification and characterization of alpha-N-acetylgalactosaminidase
	from Aspergillus niger. Appl. Microbiol. Biotechnol. (2008) 79,
	769-774. {Pubmed:18443780}
RF	<41> Tajima, Y.; Kawashima, I.; Tsukimura, T.; Sugawara, K.; Kuroda,
	M.; Suzuki, T.; Togawa, T.; Chiba, Y.; Jigami, Y.; Ohno, K.; Fukushige,
	T.; Kanekura, T.; Itoh, K.; Ohashi, T.; Sakuraba, H.: Use of a modified
	alpha-N-acetylgalactosaminidase in the development of enzyme
	replacement therapy for Fabry disease. Am. J. Hum. Genet. (2009) 85,
	569-580. {Pubmed:19853240}
RF	<42> Weignerova¡, L.; Pelantova¡, H.; Manglova¡, D.; Michalkova¡,
	K.; Kren, V.: Condensation reactions catalyzed by
	alpha-N-acetylgalactosaminidase from Aspergillus niger yielding
	alpha-N-acetylgalactosaminides. Biocatal. Biotransform. (2010) 28,
	150-155. {Pubmed:}
RF	<43> Sadik, G.; or Rashid, M.H.; Itoh-Nashida, T.; Ishii, K.; Sato, Y.;
	Shiraishi, T.; Uda, Y.: Chemical and immunological characterization of
	the two alpha-N-acetylgalactosaminidases from squid liver. Biol. Pharm.
	Bull. (2009) 32, 1469-1472. {Pubmed:19652392}
RF	<44> Harun-Or-Rashid, M.; Matsuzawa, T.; Satoh, Y.; Shiraishi, T.;
	Ando, M.; Sadik, G.; Uda, Y.: Purification and characterization of
	alpha-N-acetylgalactosaminidases I and II from the starfish Asterina
	amurensis. Biosci. Biotechnol. Biochem. (2010) 74, 256-261.
	{Pubmed:20139603}
RF	<45> Greco, M.; Mitri, M.D.; Chiriaco, F.; Leo, G.; Brienza, E.;
	Maffia, M.: Serum proteomic profile of cutaneous malignant melanoma and
	relation to cancer progression: association to tumor derived
	alpha-N-acetylgalactosaminidase activity. Cancer Lett. (2009) 283,
	222-229. {Pubmed:19394758}
RF	<46> Clark, N.E.; Garman, S.C.: The 1.9 A structure of human
	alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and
	Kanzaki diseases. J. Mol. Biol. (2009) 393, 435-447. {Pubmed:19683538}

ACTIVATING_COMPOUND
AC	#21# Trypsin (#21# the enzyme needs to be proteolytically activated,
	activation of the enzyme by trypsin <37>) <37>
AC	#3# more (#3# the enzyme is inducible in patients peripheral blood
	mononuclear cells by HIV-1 provirus-inducing agent, overview <37>) <37>

PI_VALUE
PI	#3,6# 4.8 (#6# isoelectric focusing <40>; #3# purified enzyme,
	isoelectric focusing <44>) <40,44>
PI	#35# 4.58 (#35# recombinant enzyme <46>) <46>
PI	#36# 4.4 (#36# purified isozyme alpha-GalNAcase I, isoelectric focusing
	<44>) <44>
PI	#36# 7.1 (#36# purified isozyme alpha-GalNAcase II <44>) <44>

///
ID	3.2.1.5 (deleted)
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

RECOMMENDED_NAME
RN	licheninase


SYSTEMATIC_NAME
SN	


///
